174 related articles for article (PubMed ID: 24743279)
1. [Evaluation of the antiemetic effect of aprepitant in lung cancer patients receiving carboplatin-based chemotherapy using the Functional Living Index-Emesis questionnaire].
Nagata S; Yatera K; Tokuyama S; Yamasaki K; Nishida C; Kawanami Y; Kawanami T; Ishimoto H; Mukae H
Gan To Kagaku Ryoho; 2014 Mar; 41(3):335-9. PubMed ID: 24743279
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.
Yahata H; Kobayashi H; Sonoda K; Shimokawa M; Ohgami T; Saito T; Ogawa S; Sakai K; Ichinoe A; Ueoka Y; Hasuo Y; Nishida M; Masuda S; Kato K
Int J Clin Oncol; 2016 Jun; 21(3):491-7. PubMed ID: 26662632
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy.
Kitazaki T; Fukuda Y; Fukahori S; Oyanagi K; Soda H; Nakamura Y; Kohno S
Support Care Cancer; 2015 Jan; 23(1):185-90. PubMed ID: 25063271
[TBL] [Abstract][Full Text] [Related]
4. [Study on the Antiemetic Effects of Aprepitant in Patients with Lung Cancer Receiving Chemotherapy with Carboplatin].
Hatsuyama T; Umehara K; Wakamoto A; Sato H
Gan To Kagaku Ryoho; 2015 Jun; 42(6):725-9. PubMed ID: 26199245
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy.
Uchino J; Hirano R; Tashiro N; Yoshida Y; Ushijima S; Matsumoto T; Ohta K; Nakatomi K; Takayama K; Fujita M; Nakanishi Y; Watanabe K
Asian Pac J Cancer Prev; 2012; 13(8):4187-90. PubMed ID: 23098425
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin.
Choi CH; Kim MK; Park JY; Yoon A; Kim HJ; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS
Support Care Cancer; 2014 May; 22(5):1181-7. PubMed ID: 24337621
[TBL] [Abstract][Full Text] [Related]
7. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.
Roila F; Ruggeri B; Ballatori E; Del Favero A; Tonato M
J Clin Oncol; 2014 Jan; 32(2):101-6. PubMed ID: 24323030
[TBL] [Abstract][Full Text] [Related]
8. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.
Ito Y; Karayama M; Inui N; Kuroishi S; Nakano H; Nakamura Y; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Hayakawa H; Suda T; Chida K
Lung Cancer; 2014 Jun; 84(3):259-64. PubMed ID: 24746177
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T
Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
[TBL] [Abstract][Full Text] [Related]
10. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
[TBL] [Abstract][Full Text] [Related]
11. Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Suzuki S; Karayama M; Inui N; Kuroishi S; Fujisawa T; Enomoto N; Nakamura Y; Yokomura K; Toyoshima M; Imokawa S; Asada K; Masuda M; Yamada T; Watanabe H; Hayakawa H; Suda T
Med Oncol; 2016 Jul; 33(7):65. PubMed ID: 27235141
[TBL] [Abstract][Full Text] [Related]
12. Delayed nausea and vomiting from carboplatin doublet chemotherapy.
Waqar SN; Mann J; Baggstrom MQ; Waqar MA; Chitneni P; Williams K; Gao F; Morgensztern D; Govindan R
Acta Oncol; 2016 Jun; 55(6):700-4. PubMed ID: 27145068
[TBL] [Abstract][Full Text] [Related]
13. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis.
Karayama M; Inui N; Tanaka K; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Suda T
Med Oncol; 2018 Sep; 35(11):139. PubMed ID: 30187148
[TBL] [Abstract][Full Text] [Related]
15. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
Markman MR; Peterson G; Kulp B; Markman M
Gynecol Oncol; 2002 Jun; 85(3):435-7. PubMed ID: 12051870
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
Warr DG; Street JC; Carides AD
Support Care Cancer; 2011 Jun; 19(6):807-13. PubMed ID: 20461438
[TBL] [Abstract][Full Text] [Related]
19. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails.
Hu W; Fang J; Nie J; Dai L; Chen X; Zhang J; Ma X; Tian G; Han J
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1129-36. PubMed ID: 24748417
[TBL] [Abstract][Full Text] [Related]
20. Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy.
Koshiyama M; Matsumura N; Imai S; Yamanoi K; Abiko K; Yoshioka Y; Yamaguchi K; Hamanishi J; Baba T; Konishi I
Med Sci Monit; 2017 Feb; 23():826-833. PubMed ID: 28198358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
